Joseph Gligorov

13.7k total citations
284 papers, 4.5k citations indexed

About

Joseph Gligorov is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joseph Gligorov has authored 284 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Oncology, 114 papers in Cancer Research and 73 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joseph Gligorov's work include Breast Cancer Treatment Studies (103 papers), HER2/EGFR in Cancer Research (100 papers) and Cancer Treatment and Pharmacology (91 papers). Joseph Gligorov is often cited by papers focused on Breast Cancer Treatment Studies (103 papers), HER2/EGFR in Cancer Research (100 papers) and Cancer Treatment and Pharmacology (91 papers). Joseph Gligorov collaborates with scholars based in France, Switzerland and Germany. Joseph Gligorov's co-authors include Jean Pierre Lotz, Vincent Launay‐Vacher, Jean‐François Morère, Philippe Beuzeboc, Heikki Joensuu, Stéphane Oudard, Nicolas Janus, Xavier Pourrat, Jean‐Marc Nabholtz and Gilbert Deray and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Joseph Gligorov

270 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Gligorov France 36 2.8k 1.3k 966 859 616 284 4.5k
Dario Trapani Italy 31 2.2k 0.8× 977 0.8× 1.2k 1.2× 921 1.1× 598 1.0× 201 4.3k
D. Vucicevic United States 9 1.8k 0.7× 981 0.8× 867 0.9× 1.2k 1.4× 544 0.9× 30 3.6k
Saverio Cinieri Italy 32 2.5k 0.9× 957 0.8× 930 1.0× 1.0k 1.2× 322 0.5× 206 4.3k
Serena Di Cosimo Italy 35 3.1k 1.1× 1.5k 1.2× 1.0k 1.1× 1.8k 2.1× 939 1.5× 181 5.0k
Patrizia Vici Italy 34 1.9k 0.7× 782 0.6× 680 0.7× 867 1.0× 286 0.5× 206 3.6k
Shenghui Tang United States 39 2.9k 1.0× 855 0.7× 1.8k 1.9× 1.2k 1.4× 713 1.2× 116 5.3k
Franco Nolè Italy 37 3.3k 1.2× 1.9k 1.5× 1.5k 1.5× 693 0.8× 595 1.0× 176 5.1k
Eliana Rulli Italy 33 2.6k 0.9× 687 0.5× 1.3k 1.4× 1.1k 1.2× 634 1.0× 130 4.4k
Paul G. Kluetz United States 34 1.8k 0.7× 608 0.5× 1.3k 1.3× 579 0.7× 565 0.9× 174 4.0k
Flora Zagouri Greece 33 1.7k 0.6× 873 0.7× 718 0.7× 1.2k 1.3× 241 0.4× 301 4.0k

Countries citing papers authored by Joseph Gligorov

Since Specialization
Citations

This map shows the geographic impact of Joseph Gligorov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Gligorov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Gligorov more than expected).

Fields of papers citing papers by Joseph Gligorov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Gligorov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Gligorov. The network helps show where Joseph Gligorov may publish in the future.

Co-authorship network of co-authors of Joseph Gligorov

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Gligorov. A scholar is included among the top collaborators of Joseph Gligorov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Gligorov. Joseph Gligorov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Janni, Wolfgang, Michael Untch, Nadia Harbeck, et al.. (2025). Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer. The Breast. 81. 104429–104429. 3 indexed citations
2.
3.
Fenioux, Charlotte, Yves Allenbach, Aurore Vozy, et al.. (2021). Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2. Bulletin du Cancer. 108(6). 581–588. 3 indexed citations
4.
Gougis, Paul, Fleur Cohen‐Aubart, Luca Campedel, et al.. (2021). Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis. 197. 113968–113968. 18 indexed citations
5.
Selleret, Lise, Sonia Zilberman, Joseph Gligorov, et al.. (2020). Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network. The Breast. 54. 311–318. 5 indexed citations
6.
Awada, Ahmad, Joseph Gligorov, Guy Jérusalem, et al.. (2019). CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion. ESMO Open. 4(6). e000565–e000565. 11 indexed citations
7.
Perrier, Alexandre, Joseph Gligorov, Guillaume Lefèvre, & Mathieu Boissan. (2018). The extracellular domain of Her2 in serum as a biomarker of breast cancer. Laboratory Investigation. 98(6). 696–707. 70 indexed citations
8.
Chumsri, Saranya, Jeff Sperinde, Heshan Liu, et al.. (2018). High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research. 24(13). 3053–3058. 23 indexed citations
9.
10.
11.
Richard, Sandrine, et al.. (2016). Pertuzumab and trastuzumab: the rationale way to synergy. Anais da Academia Brasileira de Ciências. 88(suppl 1). 565–577. 45 indexed citations
12.
Cutuli, B., et al.. (2015). Impact of screening on clinicopathological features and treatment for invasive breast cancer: Results of two national surveys. Cancer/Radiothérapie. 19(5). 295–302. 7 indexed citations
13.
Pierga, Jean‐Yves, Thierry Petit, Christelle Lévy, et al.. (2014). Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. Clinical Cancer Research. 21(6). 1298–1304. 45 indexed citations
14.
Pierga, Jean‐Yves, R. Delva, Xavier Pivot, et al.. (2014). Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l’étude ATHENA France. Bulletin du Cancer. 101(9). 780–788. 3 indexed citations
15.
Thibault, Constance, et al.. (2013). HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: A review. Critical Reviews in Oncology/Hematology. 88(1). 123–133. 17 indexed citations
16.
Pivot, Xavier, Joseph Gligorov, Volkmar Müller, et al.. (2013). Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology. 14(10). 962–970. 169 indexed citations
17.
Martín, Miguel, А. Н. Махсон, Joseph Gligorov, et al.. (2012). Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. The Oncologist. 17(4). 469–475. 40 indexed citations
18.
Pierga, Jean‐Yves, Thierry Petit, T. Delozier, et al.. (2012). Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. The Lancet Oncology. 13(4). 375–384. 113 indexed citations
19.
Chéreau, E., Charles Coutant, Joseph Gligorov, et al.. (2011). Discordance With Local Guidelines for Adjuvant Chemotherapy in Breast Cancer: Reasons and Effect on Survival. Clinical Breast Cancer. 11(1). 46–51. 9 indexed citations
20.
Nabholtz, Jean‐Marc & Joseph Gligorov. (2005). Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 6(9). 1555–1564. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dario Trapani Breakdown of academic impact, for papers by D. Vucicevic Breakdown of academic impact, for papers by Saverio Cinieri Breakdown of academic impact, for papers by Serena Di Cosimo Breakdown of academic impact, for papers by Patrizia Vici Breakdown of academic impact, for papers by Shenghui Tang Breakdown of academic impact, for papers by Franco Nolè Breakdown of academic impact, for papers by Eliana Rulli Breakdown of academic impact, for papers by Paul G. Kluetz Breakdown of academic impact, for papers by Flora Zagouri
Rankless by CCL
2026